Literature DB >> 32721424

Animal models of high-risk corneal transplantation: A comprehensive review.

Rohan Bir Singh1, Anna Marmalidou1, Afsaneh Amouzegar2, Yihe Chen1, Reza Dana3.   

Abstract

Over the past century, corneal transplantation has become the most commonly performed allogeneic solid tissue transplantation. Although more than 80% of the corneal transplantations have favorable outcomes, immune-mediated rejection continues to be the major cause of failure in well over 50% of graft recipients that have inflamed and vascularized host beds. Over the past two decades, the progress in our understanding of the immunological pathways that mediate graft rejection has aided in the development of novel therapeutic strategies. In order to successfully test the efficacy of these interventions, it is essential to model the immunological processes occurring as a consequence of corneal transplantation. Herein, we have comprehensively reviewed the established animal models used for replicating the immunopathological processes causing graft rejection in high-risk corneal transplantation settings. We have also discussed the practical and technical differences, as well as biological and immunological variations in different animal models.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACAID; Allergic conjunctivitis; High risk corneal transplantation; Penetrating keratoplasty; neovascularization

Year:  2020        PMID: 32721424      PMCID: PMC7508940          DOI: 10.1016/j.exer.2020.108152

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  66 in total

Review 1.  Ocular immune privilege: therapeutic opportunities from an experiment of nature.

Authors:  J Wayne Streilein
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

2.  Ocular immune privilege sites.

Authors:  Sharmila Masli; Jose L Vega
Journal:  Methods Mol Biol       Date:  2011

Review 3.  The therapeutic application of mesenchymal stem cells at the ocular surface.

Authors:  Anuradha Sahu; William Foulsham; Afsaneh Amouzegar; Sharad K Mittal; Sunil K Chauhan
Journal:  Ocul Surf       Date:  2019-01-26       Impact factor: 5.033

4.  Gamma delta T cells are needed for ocular immune privilege and corneal graft survival.

Authors:  M E Skelsey; J Mellon; J Y Niederkorn
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

5.  Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study.

Authors:  Meghan M Heberton; Shivani Tripathi; Michael Slade; Kathryn Trinkaus; Rizwan Romee; Milan Anadkat
Journal:  J Am Acad Dermatol       Date:  2019-11-02       Impact factor: 11.527

6.  GITR ligand-mediated local expansion of regulatory T cells and immune privilege of corneal allografts.

Authors:  Junko Hori; Hiroko Taniguchi; Mingcong Wang; Masamichi Oshima; Miyuki Azuma
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-11       Impact factor: 4.799

7.  Decay accelerating factor is essential for successful corneal engraftment.

Authors:  A Esposito; B Suedekum; J Liu; F An; J Lass; M G Strainic; F Lin; P Heeger; M E Medof
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

8.  Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection.

Authors:  Guillermo Amescua; Fitz Collings; Amer Sidani; Tracey L Bonfield; Juan P Rodriguez; Anat Galor; Carlos Medina; Xiaoping Yang; Victor L Perez
Journal:  Transplantation       Date:  2008-02-27       Impact factor: 4.939

9.  Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade.

Authors:  Tina Dietrich; Jasmine Onderka; Felix Bock; Friedrich E Kruse; Dörte Vossmeyer; Roland Stragies; Grit Zahn; Claus Cursiefen
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

10.  Splenic B cells act as antigen presenting cells for the induction of anterior chamber-associated immune deviation.

Authors:  Molly E Skelsey; Elizabeth Mayhew; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-12       Impact factor: 4.799

View more
  2 in total

Review 1.  Immune responses to injury and their links to eye disease.

Authors:  Mary Ann Stepp; A Sue Menko
Journal:  Transl Res       Date:  2021-05-27       Impact factor: 10.171

Review 2.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.